Syndax Corp (SNDX): Price-to-Revenue Coefficient

Symbol and logo of brand Syndax Pharmaceuticals Inc (SNDX)

Syndax Pharmaceuticals (SNDX) experienced seasoned management successfully preparing its first drugs for market entry, and GURU.Markets quotes generate this P/S ratio chart, where 2.90 expresses the current value of the metric. The company relies on an asset-light model with outsourced production, targeting the growing demand from medical centers for innovative treatments for acute leukemias.

SNDX Syndax Pharmaceuticals Inc Price-to-Revenue Ratio (07/04/2022 - 11/14/2026)

Analytical breakdowns for Syndax Corp (SNDX)

- stock price and consensus target price:
Share Price Syndax Pharmaceuticals Inc|SNDX - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Syndax Pharmaceuticals, Inc.|SNDX - Real Price to Acquire Entire Company
- company book value details:
Net Asset Value per Share Syndax Pharmaceuticals|SNDX - Company Book Value|Capitalization to Book Value Ratio syndax.com|SNDX - Company Total Assets
- business debt structure and liquidity details:
Debt to Equity Ratio Syndax Pharmaceuticals|SNDX - Long-Term Debt to Capital|Short-Term Debt to Capital Syndax Pharmaceuticals, Inc.|SNDX - Company Total Debt|Debt to Book Value Ratio Syndax Pharmaceuticals, Inc.|SNDX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Syndax Pharmaceuticals|Critical Liquidity Ratio syndax.com
- earnings and multiples data:
SNDX - Net Profit|Expected Net Income Syndax Pharmaceuticals|SNDX - P/E Multiple|Forward P/E Multiple Syndax Corp|SNDX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Syndax Pharmaceuticals|SNDX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Syndax Pharmaceuticals|SNDX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth syndax.com|SNDX - Earnings growth in current year|Expected earnings per share growth for next year Syndax Pharmaceuticals
- total revenue and sales volume data:
SNDX - Revenue and Sales Volume|Company Expected Sales Volume Syndax|SNDX - Market Cap to Revenue|Forward P/S Multiple Syndax Pharmaceuticals, Inc.
Summary company analytics:Syndax (SNDX)
Manufactured products of Syndax

To objectively assess the value of Syndax Pharmaceuticals (SNDX), it is critical for investors to compare market capitalization with actual sales revenue. By analyzing the P/S ratio, one can determine the extent to which the market overvalues or undervalues the business relative to its revenue, which is particularly relevant as Syndax Pharmaceuticals forms scientific alliances to combat rare forms of blood cancer.

Who Syndax Pharmaceuticals competes with

TG Therapeutics Corp - Market Cap to Revenue Ratio|P/S Multiple ACLX (Arcellx Inc)|IRON: Market Cap to Revenue Ratio|KURA: Market Cap to Revenue|ADCT (ADC Therapeutics) - Market Cap to Revenue Ratio|FHTX: P/S Multiple|Vor Biopharma - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio nkartatx.com|Coeptis Therapeutics, Inc. - Price-to-Sales Ratio|Price-to-Revenue Ratio Actinium Pharmaceuticals, Inc. (ATNM)|ESLA - Price to Sales|Price-to-Revenue Ratio CASI Pharmaceuticals Inc. CASI|Market Capitalization-to-Revenue Ratio MRKR|Market Capitalization-to-Revenue Ratio IN8bio Inc. (INAB)|Market Capitalization-to-Revenue Ratio ERNA (Eterna Therapeutics, Inc.)|GTBP: P/S Multiple|APTO (Aptose Biosciences Inc) - Price-to-Revenue Ratio|Market Cap to Revenue BPTH|Market Cap to Revenue MEI Pharma (MEIP)|P/S Multiple VINC